Review of current literature on gestational trophoblastic neoplasia

Journal of the Egyptian National Cancer Institute

Table 3 Treatments and remission rates in low-risk and high-risk gestational trophoblastic neoplasia

Reference	Year of Trial	Treatment arms	Complete Remission (CR) Rate	P VALUE	95% CI
Low-Risk GTN
Hao J et al.	2021	Actinomycin vs Methotrexate	80.20% vs 65.1%	0.103	1.70 – 2.73
Osborne et al.	2011	Dactinomycin vs Methotrexate	70% vs 53%	0.03	-----
Yarandi F et al.	2008	Actinomycin vs Methotrexate	90.00% vs 48.10%	<0.001	5.7 – 22.6
Aghajanian C et al.	2011	Dactinomycin vs Methotrexate	70% vs 53%
High-Risk GTN
May T et al.	2011	EMA-CO vs MFA vs MAC vs CHAMOCA	91% vs 63% vs 68% vs 71%
Lu WG et al.	2008	EMA-CO	77.8%
Matsui H et al.	2004	MEA vs FA	69.7% vs 81.8%
Aminimoghaddam S et al.	2018	EMA-EP	88%

MFA Methotrexate, folinic acid, ACT-D; CHAMOCA Cyclophosphamide, hydroxycarbamide, doxorubicin, ACT-D, Methotrexate, melphalan and Vincristine; MEA Methotrexate, Etoposide and Actinomycin D; FA 5-Fluorouracil and Actinomycin D